EVERYONE DISLIKES AWP, BUTDOCS DISLIKE PROPOSED FIXES

Article Overview

This article examines proposed Medicare payment changes for outpatient prescription drugs covered under Part B, including alternative approaches to reducing overpayments tied to average wholesale price-based reimbursement. It focuses on the expected budget impact, the role of CMS, and the concerns raised by oncology stakeholders and physician groups about practice expense reimbursement and access to care. The piece is relevant to professionals tracking Medicare reimbursement policy, drug payment methodology, and oncology practice economics.